Cells with mutant EGFR, BRAF, KRAS, or NRAS respond differently to EGFR inhibitors, BRAF inhibitors, or MEK inhibitors. a EGFR inhibitors, BRAF inhibitors, and MEK inhibitors target different components of the ERK signalling pathway, which translates growth factors through signalling components into cell proliferation and survival. Pink genes have mutations in the CGP dataset. b–d Sensitivities of wildtype cells and cells with mutant EGFR, BRAF, KRAS, or NRAS to BRAF inhibitors (b), MEK inhibitors (c), or EGFR inhibitors (d), measured as log (IC50). Statistical significance is compared with wildtype. *Adjusted p < 0.05; **adjusted p < 10−3; ***p < 10−6.